PANCREATIC DUCTAL ADENOCARCINOMA

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This early-stage trial tests a new type of cell therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy. The treatment uses a patient's own immune cells, called macrophages, that are engineered in a lab to recognize and attack cancer cells c…

This early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic…

This study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…

This study tests a new biologic drug called ANO31905 combined with standard chemotherapy as a first treatment for people with advanced pancreatic cancer that has a specific marker (CLDN18.2). The trial has two phases: first to find a safe dose, then to see if the combination shri…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to recei…

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This phase 2 trial tests whether adding nimotuzumab, a targeted antibody, to standard chemotherapy can help people with high-risk pancreatic cancer that can still be surgically removed. About 156 participants will receive either the drug combo or a placebo before and after surger…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

The EXPAND study is a research project that will enroll 440 adults with and without pancreatic conditions to understand why type 2 diabetes varies so much from person to person. Researchers will collect data on metabolism, genetics, and pancreas health to identify distinct diabet…

This study will follow 800 people, including those with chronic pancreatitis, pancreatic cancer, and healthy volunteers, to learn why some pancreatitis patients later get pancreatic cancer. Participants give blood samples and health info; some may also provide tissue samples. Res…

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…